This study is accepting new patients by invitation only

COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression

a study on COVID-19 Androgen Receptor Gene Overexpression

Summary

Eligibility
for males ages 18-90 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UC Irvine
Dates
study started
estimated completion
Principal Investigator
by Natasha Mesinkovska, MD, PhD (uci)

Description

Summary

This research study will evaluate the association of Androgen Receptor (AR) gene expression and COVID-19 disease severity and mortality. The research procedure involves collection of a single saliva sample which will be mailed to the participants by the study team. This saliva will be used in a COVID-19 Androgen Sensitivity Test (CoVAST) which will detect AR gene expression. Eligible participants are males, at least 18 years or older, and have tested positive for COVID-19.

Official Title

In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity

Keywords

Covid19, Androgen Receptor Gene Overexpression, androgen receptor, severity, mortality, COVID-19, Androgens, COVID-19 Androgen Sensitivity Test (CoVAST)

Eligibility

You can join if…

Open to males ages 18-90

  • Male over the age of 18
  • Laboratory confirmed SARS-CoV-2 infection
  • Able to give verbal informed consent

You CAN'T join if...

  • Unable to give informed consent
  • Diagnosed with an additional respiratory co-infection
  • XXY males

Locations

  • University of California, Irvine - Dermatology Clinical Research
    Irvine California 92697 United States
  • Applied Biology, Inc
    Irvine California 92614 United States

Lead Scientist at University of California Health

  • Natasha Mesinkovska, MD, PhD (uci)
    Associate Clinical Professor, Dermatology, School of Medicine. Authored (or co-authored) 130 research publications

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT04530500
Study Type
Observational
Participants
Expecting 200 study participants
Last Updated